Structured Review

Abbott Laboratories liquid chromatography tandem mass spectrometry
Liquid Chromatography Tandem Mass Spectrometry, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/liquid chromatography tandem mass spectrometry/product/Abbott Laboratories
Average 93 stars, based on 1 article reviews
Price from $9.99 to $1999.99
liquid chromatography tandem mass spectrometry - by Bioz Stars, 2020-07
93/100 stars

Images

Related Articles

Concentration Assay:

Article Title: Therapeutic potential of coenzyme Q10 in mitochondrial dysfunction during tacrolimus-induced beta cell injury
Article Snippet: .. The Tac concentration in whole-blood was measured using liquid chromatography-tandem mass spectrometry (Abbott Diagnostics, Abbott Park, IL, USA) . ..

Liquid Chromatography:

Article Title: A Pharmacokinetic and Pharmacodynamic Study of Intravenous Levosimendan in Healthy Chinese Volunteers and Ethnic Comparisons
Article Snippet: .. Plasma concentrations of levosimendan, OR1855 and OR1896 were measured by using liquid chromatography tandem mass spectrometry at the Department of Drug Analysis of Abbott Laboratories. .. Values for the pharmacokinetic parameters of levosimendan, OR1855 and OR1896, including the maximum observed plasma concentration (Cmax ), the time to Cmax (peak time, Tmax ), the terminal phase elimination rate constant (β), terminal phase elimination half-life (t1/2 ), and the area under the plasma concentration-time curve (AUC) from time 0 to the time of the last measurable concentration (AUCt ) and from time 0 to infinite time (AUC∞ ), were determined using noncompartmental methods.

Mass Spectrometry:

Article Title: A Pharmacokinetic and Pharmacodynamic Study of Intravenous Levosimendan in Healthy Chinese Volunteers and Ethnic Comparisons
Article Snippet: .. Plasma concentrations of levosimendan, OR1855 and OR1896 were measured by using liquid chromatography tandem mass spectrometry at the Department of Drug Analysis of Abbott Laboratories. .. Values for the pharmacokinetic parameters of levosimendan, OR1855 and OR1896, including the maximum observed plasma concentration (Cmax ), the time to Cmax (peak time, Tmax ), the terminal phase elimination rate constant (β), terminal phase elimination half-life (t1/2 ), and the area under the plasma concentration-time curve (AUC) from time 0 to the time of the last measurable concentration (AUCt ) and from time 0 to infinite time (AUC∞ ), were determined using noncompartmental methods.

Article Title: Therapeutic potential of coenzyme Q10 in mitochondrial dysfunction during tacrolimus-induced beta cell injury
Article Snippet: .. The Tac concentration in whole-blood was measured using liquid chromatography-tandem mass spectrometry (Abbott Diagnostics, Abbott Park, IL, USA) . ..

Chromatography:

Article Title: Therapeutic potential of coenzyme Q10 in mitochondrial dysfunction during tacrolimus-induced beta cell injury
Article Snippet: .. The Tac concentration in whole-blood was measured using liquid chromatography-tandem mass spectrometry (Abbott Diagnostics, Abbott Park, IL, USA) . ..

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 88
    Abbott Laboratories tacrolimus whole blood trough levels
    Patient disposition and reasons for discontinuation . Arm 1: Prolonged‐release <t>tacrolimus</t> (initial dose 0.2 mg/kg/day) + MMF; Arm 2: Prolonged‐release tacrolimus (initial dose 0.15–0.175 mg/kg/day) + MMF + basiliximab; Arm 3: Prolonged‐release tacrolimus (initial dose 0.2 mg/kg/day delayed until Day 5) + MMF + basiliximab. Four patients in Arm 3 had protocol violations (FAS): interruption of study medication > 7 consecutive days (two patients), SAE (one patient), and received mycophenolic acid (one patient); AEs were given as the primary reason for discontinuation by the study investigators. The types of AEs leading to discontinuation were not reported, as patients may have had multiple AEs at the time of discontinuation. AE, adverse event; FAS, full‐analysis set; mITT, modified intent to treat; MMF, mycophenolate mofetil; PPS, per‐protocol set; SAF, safety‐analysis set; SAE, serious adverse event.
    Tacrolimus Whole Blood Trough Levels, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tacrolimus whole blood trough levels/product/Abbott Laboratories
    Average 88 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    tacrolimus whole blood trough levels - by Bioz Stars, 2020-07
    88/100 stars
      Buy from Supplier

    91
    Abbott Laboratories fish probe kit
    Development of <t>ALK</t> SRM assay and assessment of assay precision (A), Calibration curve generated in Pfu . Inset, Calibration curve omitting the 3 highest concentrations (25 000, 5000, and 1000 amol). (B), Assessment of assay precision and reproducibility for measuring ALK protein concentrations in 8 ALK <t>FISH</t> + NSCLC FFPE tumor tissues. Each sample was analyzed on 2 different LC-MS systems.
    Fish Probe Kit, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 91/100, based on 111 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fish probe kit/product/Abbott Laboratories
    Average 91 stars, based on 111 article reviews
    Price from $9.99 to $1999.99
    fish probe kit - by Bioz Stars, 2020-07
    91/100 stars
      Buy from Supplier

    93
    Abbott Laboratories cd4 t cells
    Cholesterol biosynthesis pathway inhibition interferes with c-Maf expression. Purified human CD4 +  T cells stimulated in vitro with plate-bound α-CD3 (2 μgml −1 ) + α-CD46 (5 μgml −1 ) and recombinant human interleukin-2 (rhIL-2) (50 Uml −1 ) were cultured for 36 h in the presence of 25-hydroxycholesterol (25-HC).  a  Expression levels of  MAF  mRNA ( n  = 7).  b  Expression levels of  PRDM1  mRNA ( n  = 6).  c  Representative flow cytometric analysis of intracellular c-Maf staining.  d  Normalised frequency of c-Maf +  cells ( n  = 16).  e  Normalised frequency of c-Maf +  cells cultured under fully supplemented medium (M) and cholesterol (500×) (Ch) in the presence or absence of 2μM 25-HC ( n  = 3).  f  Correlation between frequency of c-Maf +  and IL-10 +  cells, numbers denote  r  and  p  values for Spearman's correlation test. Graphs show independent donors (dots) normalised to untreated cells; bars represent median values. *
    Cd4 T Cells, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 93/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd4 t cells/product/Abbott Laboratories
    Average 93 stars, based on 2 article reviews
    Price from $9.99 to $1999.99
    cd4 t cells - by Bioz Stars, 2020-07
    93/100 stars
      Buy from Supplier

    92
    Abbott Laboratories lopinavir
    <t>Lopinavir</t> and ritonavir concentrations in an HIV infected child determined by HPLC-UV and by MALDI-triple quadrupole MS. Pharmacokinetic curve of lopinavir and ritonavir in one HIV infected child determined by HPLC-UV (triangles for lopinavir and crosses for ritonavir), MALDI-triple quadrupole MS (diamonds for lopinavir and circles for ritonavir), and MALDI-triple quadrupole MS when ten additional drugs (10 µM per drug) were spiked to the patient's samples (squares for lopinavir and pluses for ritonavir).
    Lopinavir, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 92/100, based on 23 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/lopinavir/product/Abbott Laboratories
    Average 92 stars, based on 23 article reviews
    Price from $9.99 to $1999.99
    lopinavir - by Bioz Stars, 2020-07
    92/100 stars
      Buy from Supplier

    Image Search Results


    Patient disposition and reasons for discontinuation . Arm 1: Prolonged‐release tacrolimus (initial dose 0.2 mg/kg/day) + MMF; Arm 2: Prolonged‐release tacrolimus (initial dose 0.15–0.175 mg/kg/day) + MMF + basiliximab; Arm 3: Prolonged‐release tacrolimus (initial dose 0.2 mg/kg/day delayed until Day 5) + MMF + basiliximab. Four patients in Arm 3 had protocol violations (FAS): interruption of study medication > 7 consecutive days (two patients), SAE (one patient), and received mycophenolic acid (one patient); AEs were given as the primary reason for discontinuation by the study investigators. The types of AEs leading to discontinuation were not reported, as patients may have had multiple AEs at the time of discontinuation. AE, adverse event; FAS, full‐analysis set; mITT, modified intent to treat; MMF, mycophenolate mofetil; PPS, per‐protocol set; SAF, safety‐analysis set; SAE, serious adverse event.

    Journal: American Journal of Transplantation

    Article Title: Renal Function in De Novo Liver Transplant Recipients Receiving Different Prolonged‐Release Tacrolimus Regimens—The DIAMOND Study

    doi: 10.1111/ajt.13182

    Figure Lengend Snippet: Patient disposition and reasons for discontinuation . Arm 1: Prolonged‐release tacrolimus (initial dose 0.2 mg/kg/day) + MMF; Arm 2: Prolonged‐release tacrolimus (initial dose 0.15–0.175 mg/kg/day) + MMF + basiliximab; Arm 3: Prolonged‐release tacrolimus (initial dose 0.2 mg/kg/day delayed until Day 5) + MMF + basiliximab. Four patients in Arm 3 had protocol violations (FAS): interruption of study medication > 7 consecutive days (two patients), SAE (one patient), and received mycophenolic acid (one patient); AEs were given as the primary reason for discontinuation by the study investigators. The types of AEs leading to discontinuation were not reported, as patients may have had multiple AEs at the time of discontinuation. AE, adverse event; FAS, full‐analysis set; mITT, modified intent to treat; MMF, mycophenolate mofetil; PPS, per‐protocol set; SAF, safety‐analysis set; SAE, serious adverse event.

    Article Snippet: Tacrolimus whole blood trough levels were monitored using microparticle enzyme immunoassay (IMX® ), chemiluminescent microparticle immunoassay (Abbott Diagnostics), enzyme‐multiplied immunoassay, antibody‐conjugated magnetic immunoassay (Siemens Diagnostics), or high‐performance liquid chromatography tandem mass spectrometry, according to local practice.

    Techniques: Modification

    Mean tacrolimus trough levels (a) in the first 35 days posttransplant and (b) throughout the study period, stratified by treatment arm over 24 weeks of treatment (FAS). Error bars represent standard error of mean. In Arm 3, three patients received prolonged‐release tacrolimus before Day 5. FAS, full‐analysis set; MMF, mycophenolate mofetil.

    Journal: American Journal of Transplantation

    Article Title: Renal Function in De Novo Liver Transplant Recipients Receiving Different Prolonged‐Release Tacrolimus Regimens—The DIAMOND Study

    doi: 10.1111/ajt.13182

    Figure Lengend Snippet: Mean tacrolimus trough levels (a) in the first 35 days posttransplant and (b) throughout the study period, stratified by treatment arm over 24 weeks of treatment (FAS). Error bars represent standard error of mean. In Arm 3, three patients received prolonged‐release tacrolimus before Day 5. FAS, full‐analysis set; MMF, mycophenolate mofetil.

    Article Snippet: Tacrolimus whole blood trough levels were monitored using microparticle enzyme immunoassay (IMX® ), chemiluminescent microparticle immunoassay (Abbott Diagnostics), enzyme‐multiplied immunoassay, antibody‐conjugated magnetic immunoassay (Siemens Diagnostics), or high‐performance liquid chromatography tandem mass spectrometry, according to local practice.

    Techniques:

    Development of ALK SRM assay and assessment of assay precision (A), Calibration curve generated in Pfu . Inset, Calibration curve omitting the 3 highest concentrations (25 000, 5000, and 1000 amol). (B), Assessment of assay precision and reproducibility for measuring ALK protein concentrations in 8 ALK FISH + NSCLC FFPE tumor tissues. Each sample was analyzed on 2 different LC-MS systems.

    Journal: Clinical chemistry

    Article Title: Quantification of Anaplastic Lymphoma Kinase Protein Expression in Non–Small Cell Lung Cancer Tissues from Patients Treated with Crizotinib

    doi: 10.1373/clinchem.2015.245860

    Figure Lengend Snippet: Development of ALK SRM assay and assessment of assay precision (A), Calibration curve generated in Pfu . Inset, Calibration curve omitting the 3 highest concentrations (25 000, 5000, and 1000 amol). (B), Assessment of assay precision and reproducibility for measuring ALK protein concentrations in 8 ALK FISH + NSCLC FFPE tumor tissues. Each sample was analyzed on 2 different LC-MS systems.

    Article Snippet: ALK FISH results had been obtained with the ALK Break Apart FISH Probe Kit (Abbott Laboratories).

    Techniques: Generated, Fluorescence In Situ Hybridization, Formalin-fixed Paraffin-Embedded, Liquid Chromatography with Mass Spectroscopy

    Comparison of SRM with ALK FISH, IHC, and DNA sequencing in selective cases FISH and paired IHC for patient DH5 to represent FISH + /IHC + cases; DNA sequence within the MS targeted peptide from DH1 to represent wild-type sequence. (A), ALK FISH testing shows deletion of the 5 ′ (green) signal with retained 3 ′ (orange) signal, consistent with rearrangement. Arrows indicate the rearranged red signal. (B), The FISH + , SRM − , and IHC − case (DH9) showed a nonsense point mutation that resulted in a stop codon (p.Q1429X); therefore, nonfunctional fusion protein would be produced.

    Journal: Clinical chemistry

    Article Title: Quantification of Anaplastic Lymphoma Kinase Protein Expression in Non–Small Cell Lung Cancer Tissues from Patients Treated with Crizotinib

    doi: 10.1373/clinchem.2015.245860

    Figure Lengend Snippet: Comparison of SRM with ALK FISH, IHC, and DNA sequencing in selective cases FISH and paired IHC for patient DH5 to represent FISH + /IHC + cases; DNA sequence within the MS targeted peptide from DH1 to represent wild-type sequence. (A), ALK FISH testing shows deletion of the 5 ′ (green) signal with retained 3 ′ (orange) signal, consistent with rearrangement. Arrows indicate the rearranged red signal. (B), The FISH + , SRM − , and IHC − case (DH9) showed a nonsense point mutation that resulted in a stop codon (p.Q1429X); therefore, nonfunctional fusion protein would be produced.

    Article Snippet: ALK FISH results had been obtained with the ALK Break Apart FISH Probe Kit (Abbott Laboratories).

    Techniques: Fluorescence In Situ Hybridization, Immunohistochemistry, DNA Sequencing, Sequencing, Mass Spectrometry, Mutagenesis, Produced

    Cholesterol biosynthesis pathway inhibition interferes with c-Maf expression. Purified human CD4 +  T cells stimulated in vitro with plate-bound α-CD3 (2 μgml −1 ) + α-CD46 (5 μgml −1 ) and recombinant human interleukin-2 (rhIL-2) (50 Uml −1 ) were cultured for 36 h in the presence of 25-hydroxycholesterol (25-HC).  a  Expression levels of  MAF  mRNA ( n  = 7).  b  Expression levels of  PRDM1  mRNA ( n  = 6).  c  Representative flow cytometric analysis of intracellular c-Maf staining.  d  Normalised frequency of c-Maf +  cells ( n  = 16).  e  Normalised frequency of c-Maf +  cells cultured under fully supplemented medium (M) and cholesterol (500×) (Ch) in the presence or absence of 2μM 25-HC ( n  = 3).  f  Correlation between frequency of c-Maf +  and IL-10 +  cells, numbers denote  r  and  p  values for Spearman's correlation test. Graphs show independent donors (dots) normalised to untreated cells; bars represent median values. *

    Journal: Nature Communications

    Article Title: The cholesterol biosynthesis pathway regulates IL-10 expression in human Th1 cells

    doi: 10.1038/s41467-019-08332-9

    Figure Lengend Snippet: Cholesterol biosynthesis pathway inhibition interferes with c-Maf expression. Purified human CD4 + T cells stimulated in vitro with plate-bound α-CD3 (2 μgml −1 ) + α-CD46 (5 μgml −1 ) and recombinant human interleukin-2 (rhIL-2) (50 Uml −1 ) were cultured for 36 h in the presence of 25-hydroxycholesterol (25-HC). a Expression levels of MAF mRNA ( n  = 7). b Expression levels of PRDM1 mRNA ( n  = 6). c Representative flow cytometric analysis of intracellular c-Maf staining. d Normalised frequency of c-Maf + cells ( n  = 16). e Normalised frequency of c-Maf + cells cultured under fully supplemented medium (M) and cholesterol (500×) (Ch) in the presence or absence of 2μM 25-HC ( n  = 3). f Correlation between frequency of c-Maf + and IL-10 + cells, numbers denote r and p values for Spearman's correlation test. Graphs show independent donors (dots) normalised to untreated cells; bars represent median values. *

    Article Snippet: For adalimumab experiments, CD4+ T cells and CD14+ monocytes (1 × 106 ml−1 ) were co-cultured with 100 ng ml−1 CD3 mAb and 1 μgml−1 adalimumab (Abbott) for 3 days , .

    Techniques: Inhibition, Expressing, Purification, In Vitro, Recombinant, Cell Culture, Flow Cytometry, Staining

    Metabolic regulation of T-helper type 1 (Th1) switching in primary human CD4 +  T cells.  a  Schematic flow cytometric dot-plot of the life cycle of human Th1 switching; double-positive cells are highlighted with a blue gate, while IL-10-negative populations are shown within a black gate;  b  Heatmap of 111 significantly expressed genes in the double-negative (IFNγ − IL-10 − ) and single-positive (IFNγ + IL-10 − ) populations associated with changes in IL-10 protein expression, as measured by median fluorescence intensity ratio (MFI + :MFI − ) for IL-10 expression in the double-positive (IFNγ + IL-10 + ) population.  c  Ingenuity Pathway Analysis (IPA) based on genes from  b  (SP: superpathway). Bars represent the percentage of the number of genes mapping to a particular pathway, coloured in green to note the inverse correlation. The number indicates the number of total genes ascribed to the pathway. The yellow line represents the  P  value as calculated by Fisher’s test and corrected for multiple testing using the Benjamini–Hochberg correction.  d  IPA based on genes differentially expressed between CYT-1- and CYT-2-expressing Jurkat T cells and analysed and annotated as in  c

    Journal: Nature Communications

    Article Title: The cholesterol biosynthesis pathway regulates IL-10 expression in human Th1 cells

    doi: 10.1038/s41467-019-08332-9

    Figure Lengend Snippet: Metabolic regulation of T-helper type 1 (Th1) switching in primary human CD4 + T cells. a Schematic flow cytometric dot-plot of the life cycle of human Th1 switching; double-positive cells are highlighted with a blue gate, while IL-10-negative populations are shown within a black gate; b Heatmap of 111 significantly expressed genes in the double-negative (IFNγ − IL-10 − ) and single-positive (IFNγ + IL-10 − ) populations associated with changes in IL-10 protein expression, as measured by median fluorescence intensity ratio (MFI + :MFI − ) for IL-10 expression in the double-positive (IFNγ + IL-10 + ) population. c Ingenuity Pathway Analysis (IPA) based on genes from b (SP: superpathway). Bars represent the percentage of the number of genes mapping to a particular pathway, coloured in green to note the inverse correlation. The number indicates the number of total genes ascribed to the pathway. The yellow line represents the P value as calculated by Fisher’s test and corrected for multiple testing using the Benjamini–Hochberg correction. d IPA based on genes differentially expressed between CYT-1- and CYT-2-expressing Jurkat T cells and analysed and annotated as in c

    Article Snippet: For adalimumab experiments, CD4+ T cells and CD14+ monocytes (1 × 106 ml−1 ) were co-cultured with 100 ng ml−1 CD3 mAb and 1 μgml−1 adalimumab (Abbott) for 3 days , .

    Techniques: Flow Cytometry, Expressing, Fluorescence, Indirect Immunoperoxidase Assay

    T-helper type 1 (Th1) switching to interleukin-10 (IL-10) is blocked when the mevalonate pathway is inhibited. Purified human CD4 +  T cells stimulated in vitro with plate-bound α-CD3 (2 μgml −1 ) + α-CD46 (5 μgml −1 ) and recombinant human interleukin-2 (rhIL-2) (50 Uml −1 ) were cultured for 36 h in the presence of atorvastatin and 250 μM mevalonic acid (MA) as indicated, unless stated otherwise.  a  Representative flow cytometric analysis of intracellular interferon-γ (IFNγ) and IL-10 staining.  b  Normalised frequency of IFNγ − IL-10 + - (left), IFNγ + IL-10 + - (centre) and IFNγ + IL-10 − - (right) producing cells ( n  = 20).  c  Normalised concentration of secreted IL-10 ( n  = 19).  d  Normalised  IL10  messenger RNA (mRNA) levels ( n  = 8).  e  Representative flow cytometric analysis of intracellular IL-17 (top) and tumour necrosis factor-α (TNFα) (bottom) co-stained with IL-10 of atorvastatin-treated cells (cumulative data shown in supplementary Fig.   3g ).  f  Normalised concentration of secreted IL-4 ( n  = 9).  g  Effect of atorvastatin (AT) treatment on purified CD4 +  cells co-cultured with monocytes and α-CD3 (100 ng ml −1 ) in the absence or presence of Adalimumab (1 μgml −1 ). Data show a representative dot-plot for intracellular IL-10 and IFNγ production (cumulative data shown in Supplementary Fig.   3h ). Graphs show independent donors (dots) normalised to 0 μM dose of atorvastatin; bars represent median values. *

    Journal: Nature Communications

    Article Title: The cholesterol biosynthesis pathway regulates IL-10 expression in human Th1 cells

    doi: 10.1038/s41467-019-08332-9

    Figure Lengend Snippet: T-helper type 1 (Th1) switching to interleukin-10 (IL-10) is blocked when the mevalonate pathway is inhibited. Purified human CD4 + T cells stimulated in vitro with plate-bound α-CD3 (2 μgml −1 ) + α-CD46 (5 μgml −1 ) and recombinant human interleukin-2 (rhIL-2) (50 Uml −1 ) were cultured for 36 h in the presence of atorvastatin and 250 μM mevalonic acid (MA) as indicated, unless stated otherwise. a Representative flow cytometric analysis of intracellular interferon-γ (IFNγ) and IL-10 staining. b Normalised frequency of IFNγ − IL-10 + - (left), IFNγ + IL-10 + - (centre) and IFNγ + IL-10 − - (right) producing cells ( n  = 20). c Normalised concentration of secreted IL-10 ( n  = 19). d Normalised IL10 messenger RNA (mRNA) levels ( n  = 8). e Representative flow cytometric analysis of intracellular IL-17 (top) and tumour necrosis factor-α (TNFα) (bottom) co-stained with IL-10 of atorvastatin-treated cells (cumulative data shown in supplementary Fig.  3g ). f Normalised concentration of secreted IL-4 ( n  = 9). g Effect of atorvastatin (AT) treatment on purified CD4 + cells co-cultured with monocytes and α-CD3 (100 ng ml −1 ) in the absence or presence of Adalimumab (1 μgml −1 ). Data show a representative dot-plot for intracellular IL-10 and IFNγ production (cumulative data shown in Supplementary Fig.  3h ). Graphs show independent donors (dots) normalised to 0 μM dose of atorvastatin; bars represent median values. *

    Article Snippet: For adalimumab experiments, CD4+ T cells and CD14+ monocytes (1 × 106 ml−1 ) were co-cultured with 100 ng ml−1 CD3 mAb and 1 μgml−1 adalimumab (Abbott) for 3 days , .

    Techniques: Purification, In Vitro, Recombinant, Cell Culture, Flow Cytometry, Staining, Concentration Assay

    Interleukin (IL-10) expression in T-helper type 1 (Th1) switching cells is dependent on intact cholesterol pathway fitness. Purified human CD4 +  T cells stimulated in vitro with plate-bound α-CD3 (2 μgml −1 ) + α-CD46 (5 μgml −1 ) and recombinant human interleukin-2 (rhIL-2) (50 Uml −1 ) were cultured for 36 h in the presence of 25-hydroxycholesterol (25-HC).  a  Normalised  LDLr ,  HMGCS1 ,  FDFT1  and  DHCR7  messenger RNA (mRNA) levels ( n  = 6–7).  b  Representative flow cytometric analysis of intracellular interferon-γ (IFNγ) and IL-10 staining.  c  Normalised frequency of IFNγ − IL-10 + - (left), IFNγ + IL-10 + - (centre) and IFNγ + IL-10 − - (right) producing cells ( n  = 16).  d  Normalised concentrations of secreted IL-10 ( n  = 9).  e  Normalised frequency of IFNγ − IL-10 + - (left), IFNγ + IL-10 + - (centre) and IFNγ + IL-10 − - (right) producing cells cultured under lipid-free medium (LFM), fully supplemented medium (M) and cholesterol (500×) (Ch) in the presence or absence of 25-HC (2μM) for 36 h ( n  = 7). Graphs show independent donors (dots) normalised to untreated cells; bars represent median values. *

    Journal: Nature Communications

    Article Title: The cholesterol biosynthesis pathway regulates IL-10 expression in human Th1 cells

    doi: 10.1038/s41467-019-08332-9

    Figure Lengend Snippet: Interleukin (IL-10) expression in T-helper type 1 (Th1) switching cells is dependent on intact cholesterol pathway fitness. Purified human CD4 + T cells stimulated in vitro with plate-bound α-CD3 (2 μgml −1 ) + α-CD46 (5 μgml −1 ) and recombinant human interleukin-2 (rhIL-2) (50 Uml −1 ) were cultured for 36 h in the presence of 25-hydroxycholesterol (25-HC). a Normalised LDLr , HMGCS1 , FDFT1 and DHCR7 messenger RNA (mRNA) levels ( n  = 6–7). b Representative flow cytometric analysis of intracellular interferon-γ (IFNγ) and IL-10 staining. c Normalised frequency of IFNγ − IL-10 + - (left), IFNγ + IL-10 + - (centre) and IFNγ + IL-10 − - (right) producing cells ( n  = 16). d Normalised concentrations of secreted IL-10 ( n  = 9). e Normalised frequency of IFNγ − IL-10 + - (left), IFNγ + IL-10 + - (centre) and IFNγ + IL-10 − - (right) producing cells cultured under lipid-free medium (LFM), fully supplemented medium (M) and cholesterol (500×) (Ch) in the presence or absence of 25-HC (2μM) for 36 h ( n  = 7). Graphs show independent donors (dots) normalised to untreated cells; bars represent median values. *

    Article Snippet: For adalimumab experiments, CD4+ T cells and CD14+ monocytes (1 × 106 ml−1 ) were co-cultured with 100 ng ml−1 CD3 mAb and 1 μgml−1 adalimumab (Abbott) for 3 days , .

    Techniques: Expressing, Purification, In Vitro, Recombinant, Cell Culture, Flow Cytometry, Staining

    Interleukin (IL-10) regulation in T-helper type 1 (Th1) switching cells is not dependent on isoprenylation, vitamin D3 or cellular cholesterol content. Purified human CD4 +  T cells stimulated in vitro with plate-bound α-CD3 (2 μgml −1 ) + α-CD46 (5 μgml −1 ) and recombinant human interleukin-2 (rhIL-2) (50Uml −1 ) were cultured for 36 h in the presence of selected metabolites and inhibitors as indicated.  a  Representative flow cytometric analysis of intracellular interferon-γ (IFNγ) and IL-10 staining of cells treated with different formulations of statin (data representative of three independent donors).  b  Normalised frequency of IL-10 +  cells cultured in the presence of inhibitors for farnesyl-PP transferase (FTase I inhibitor) (left) ( n  = 4), geranylgenaryl transferase I (GGTI-298) (centre) ( n  = 4) and Rab geranylgeranyl transferase (psoromic acid) (right) ( n  = 5).  c  Normalised frequency of IL-10 +  cells cultured with 5μM atorvastatin (AT) and increasing concentrations of farnesylpyrophosphate (FPP) (left) and geranylgeranylphyrophosphate (GGPP) (right) and mevalonic acid (MA) as control ( n  = 5).  d  Normalised frequency of IL-10 +  cells cultured in the presence of increasing concentrations of U18666A ( n  = 6).  e  Normalised frequency of IL-10 +  cells cultured with 5 μM atorvastatin (AT) and increasing concentrations of calcitriol and mevalonic acid (MA) as a control ( n  = 5).  f  Normalised total cellular cholesterol content measured by liquid chromatography mass spectrometry. The [cholesterol –H 2 O + H] +  ion was the dominant adduct for cholesterol and relative intensity is shown for this ion ( n  = 3). Graphs show independent donors (dots) normalised to 0μM dose of atorvastatin; bars represent median values. *

    Journal: Nature Communications

    Article Title: The cholesterol biosynthesis pathway regulates IL-10 expression in human Th1 cells

    doi: 10.1038/s41467-019-08332-9

    Figure Lengend Snippet: Interleukin (IL-10) regulation in T-helper type 1 (Th1) switching cells is not dependent on isoprenylation, vitamin D3 or cellular cholesterol content. Purified human CD4 + T cells stimulated in vitro with plate-bound α-CD3 (2 μgml −1 ) + α-CD46 (5 μgml −1 ) and recombinant human interleukin-2 (rhIL-2) (50Uml −1 ) were cultured for 36 h in the presence of selected metabolites and inhibitors as indicated. a Representative flow cytometric analysis of intracellular interferon-γ (IFNγ) and IL-10 staining of cells treated with different formulations of statin (data representative of three independent donors). b Normalised frequency of IL-10 + cells cultured in the presence of inhibitors for farnesyl-PP transferase (FTase I inhibitor) (left) ( n  = 4), geranylgenaryl transferase I (GGTI-298) (centre) ( n  = 4) and Rab geranylgeranyl transferase (psoromic acid) (right) ( n  = 5). c Normalised frequency of IL-10 + cells cultured with 5μM atorvastatin (AT) and increasing concentrations of farnesylpyrophosphate (FPP) (left) and geranylgeranylphyrophosphate (GGPP) (right) and mevalonic acid (MA) as control ( n  = 5). d Normalised frequency of IL-10 + cells cultured in the presence of increasing concentrations of U18666A ( n  = 6). e Normalised frequency of IL-10 + cells cultured with 5 μM atorvastatin (AT) and increasing concentrations of calcitriol and mevalonic acid (MA) as a control ( n  = 5). f Normalised total cellular cholesterol content measured by liquid chromatography mass spectrometry. The [cholesterol –H 2 O + H] + ion was the dominant adduct for cholesterol and relative intensity is shown for this ion ( n  = 3). Graphs show independent donors (dots) normalised to 0μM dose of atorvastatin; bars represent median values. *

    Article Snippet: For adalimumab experiments, CD4+ T cells and CD14+ monocytes (1 × 106 ml−1 ) were co-cultured with 100 ng ml−1 CD3 mAb and 1 μgml−1 adalimumab (Abbott) for 3 days , .

    Techniques: Purification, In Vitro, Recombinant, Cell Culture, Flow Cytometry, Staining, Liquid Chromatography, Mass Spectrometry

    Lopinavir and ritonavir concentrations in an HIV infected child determined by HPLC-UV and by MALDI-triple quadrupole MS. Pharmacokinetic curve of lopinavir and ritonavir in one HIV infected child determined by HPLC-UV (triangles for lopinavir and crosses for ritonavir), MALDI-triple quadrupole MS (diamonds for lopinavir and circles for ritonavir), and MALDI-triple quadrupole MS when ten additional drugs (10 µM per drug) were spiked to the patient's samples (squares for lopinavir and pluses for ritonavir).

    Journal: PLoS ONE

    Article Title: Ultra-Fast Analysis of Plasma and Intracellular Levels of HIV Protease Inhibitors in Children: A Clinical Application of MALDI Mass Spectrometry

    doi: 10.1371/journal.pone.0011409

    Figure Lengend Snippet: Lopinavir and ritonavir concentrations in an HIV infected child determined by HPLC-UV and by MALDI-triple quadrupole MS. Pharmacokinetic curve of lopinavir and ritonavir in one HIV infected child determined by HPLC-UV (triangles for lopinavir and crosses for ritonavir), MALDI-triple quadrupole MS (diamonds for lopinavir and circles for ritonavir), and MALDI-triple quadrupole MS when ten additional drugs (10 µM per drug) were spiked to the patient's samples (squares for lopinavir and pluses for ritonavir).

    Article Snippet: Chemicals and solvents Methotrexate (Emthexate PF for parenteral administration, PharmaChemie BV, Haarlem, the Netherlands), saquinavir (donated by F.Hoffmann La-Roche, Basel, Switzerland), indinavir (donated by Merck, Rahway, NJ, USA), nelfinavir (donated by Pfizer, Groton, CT, USA), lopinavir and ritonavir (donated by Abbott Laboratories, Illinois, IL, USA), Kaletra oral solution (80 mg/mL lopinavir and 20 mg/mL ritonavir; Abbott; obtained from dept.

    Techniques: Infection, High Performance Liquid Chromatography, Mass Spectrometry